
April 15 (Reuters) - Hoth Therapeutics Inc HOTH.O:
HOTH THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA IN PHASE 2A CLINICAL TRIAL
HOTH THERAPEUTICS INC - PATIENTS EXPERIENCED A 50% REDUCTION IN PRURITUS SEVERITY, WITH MEAN SCORES DROPPING FROM 1.6 ON DAY 1 TO 0.8 BY DAY 21
HOTH THERAPEUTICS INC - HT-001 WAS WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED